Aldagen Cancels IPO
Aldagen Inc., a Durham, N.C.-based developer of clinical-stage regenerative therapies, has withdrawn registration for an $80.5 million IPO, due to “market conditions.” It had planned to trade on the Nasdaq, with Wachovia Securities and Cowen & Co. serving as co-lead underwriters.
Aldagen has raised around $65 million in VC funding since 2000, from firms like Intersouth Partners (41.6% pre-IPO stake), Harbert Venture Partners (14.7%), The Aurora Funds (12.3%), Tullis-Dickerson (9.3%) and Trelys Funds (5.4%). www.aldegen.com
Related posts:








